



## IMRICOR SUBMITS NORTHSTAR FOR U.S. PEDIATRIC EXPANSION

**08 April 2026** – Melbourne, Australia (**07 April 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** is pleased to announce that it has submitted its NorthStar® Mapping System to the U.S. Food and Drug Administration (FDA) for pediatric label expansion via the FDA’s Special 510(k) pathway.

The submission follows Imricor’s announcement in January 2026 that NorthStar had received FDA clearance for use in adult patients. The submission to expand NorthStar to include use with pediatric patients represents another important step in the Company’s U.S. commercialization strategy.

Imricor has received inbound interest from children’s hospitals across the United States following the FDA clearance of NorthStar. The pediatric label expansion is intended to enable Imricor to proactively market NorthStar into this important customer segment and to support the establishment of an installed base in pediatric centres around the U.S. during 2026. There are over 250 children’s hospitals in the United States.

The Company believes the pediatric market represents an attractive early commercial channel for NorthStar in advance of broader U.S. adoption of Imricor’s full EP platform in adult hospitals. Children’s hospitals often have a strong interest in reducing radiation exposure for their patients, and as navigation system for use in interventional cardiovascular magnetic resonance (iCMR) procedures, NorthStar may be well suited to adapt and improve iCMR procedure workflows currently performed with only stock MRI system interfaces. Importantly, the Company can already sell NorthStar to Children’s hospitals who have proactively contacted the Company.

If cleared, the pediatric label expansion would allow Imricor to **proactively market** NorthStar for use in pediatric cases, broadening the addressable market for the system and strengthening the Company’s commercial momentum in the United States. Clearance is expected in the current quarter.

**Imricor’s Chair and CEO, Steve Wedan, commented:** “Submitting NorthStar for a label expansion into pediatrics is an exciting and practical step to accelerate our U.S. commercialization strategy. Since receiving FDA clearance for NorthStar earlier this year, we have seen meaningful interest from children’s hospitals and have already begun engaging with these in-bound prospective customers.

“We believe pediatric centres can become an important channel for NorthStar adoption in the U.S. Establishing an installed base in these hospitals has the potential to generate revenue, expand awareness of our technology, and position Imricor strongly as we continue working toward broader rollout of our full EP platform in adult hospitals.

“We are moving very quickly to translate regulatory progress into clinical adoption and commercial traction, and this submission reflects our strategy of opening multiple paths to market NorthStar in the U.S. This submission highlights that we are not just an iCMR ablation company. We are, more broadly, an interventional **MR** company. We are iMR.”

### ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

For personal use only



## Media and Investor Relations Contacts:

Simon Hinsley  
Executive Director, NWR  
simon@nwrcommunications.com.au  
+61 401 909 653

Nick Corkill  
VP Corporate Strategy, Imricor  
nick.corkill@imricor.com  
+61 450 475 633

## About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

## Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

## Foreign Ownership Restrictions

Imricor's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

## Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only